Sanofi's Lemtrada Shines in Extended Study

Sanofi’s (NYSE: SNY  ) multiple sclerosis drug Lemtrada showed strong results in the first year of an extended phase 3 study, reducing relapse rates in treated patients and improved disability outcomes, the company said this week.

The study results [file opens in PDF], released by Sanofi and subsidiary Genzyme, came as the European Medicines Agency and the FDA review Lemtrada for regulatory decisions expected later in 2013.

Sixty-seven percent of patients new to treatment and 55% of patients who had relapsed on prior therapy remained relapse-free a year into the extended study. More than 70% of each patient group showed improved or stable disability, while more than 80% of patients didn’t require a third round of treatment during the trial.

Lemtrada’s safety profile remained steady as no new risks emerged for patients on the drug; infections were the most common adverse events over the course of the extended study’s first year. 

link


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 11, 2013, at 12:19 PM, ikkyu2 wrote:

    If you want a pure play on Lemtrada, you can buy Genzyme Contingent Value Rights, GCVRZ. These are a kind of warrant which have value if Lemtrada meets certain sales targets.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2327880, ~/Articles/ArticleHandler.aspx, 11/29/2014 12:04:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement